EQS-News

Innovative Drug Update Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10 04.06.2026, 13:15 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Kexing Biopharm / Key word(s): Miscellaneous
Innovative Drug Update Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

04.06.2026 / 13:15 CET/CEST
The issuer is solely responsible for the content of this announcement.


SHENZHEN, China, June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), a wholly-owned subsidiary of Kexing Biopharm. Designed to treat neovascular age-related macular degeneration (nAMD), the progress of GB10 marks a significant milestone in the Company's accelerating innovative drug R&D pipeline.

GB10 is a high-concentration, ophthalmic protein drug formulation independently developed by Shenzhen Kexing. It features a bispecific antibody targeting both VEGF and Ang-2. With a high concentration of 140 mg/mL, GB10 Injection allows for a smaller injection volume or higher dosage, thereby extending the dosing interval. It is expected to achieve a "once per four months" dosing schedule, significantly improving patient compliance. Preclinical data indicate international competitiveness of GB10 Injection in terms of both biological activity and in vivo efficacy. In a laser-induced choroidal neovascularization (CNV) monkey model, it demonstrated effective inhibition of pathological ocular neovascularization in the fundus.

Neovascular age-related macular degeneration (nAMD) remains a leading cause of blindness globally among individuals aged over 50. Driven by the rapid growth of the internet, increased screen time, and an aging population, the clinical demand for ophthalmic treatments is surging. Therapeutic regimens with extended dosing intervals address critical clinical pain points, such as high injection frequency and poor patient compliance.

Kexing Biopharm is simultaneously accelerating its independent R&D of dual-target antibody ophthalmic pipeline and actively introducing externally developed ophthalmic products for international markets, including Aflibercept biosimilars and Olopatadine Hydrochloride eye drops. These efforts aim to expand its global footprint and drive internationalization through continuous innovation.

Looking ahead, the Company will adhere to its philosophy of "Precise Products, Predictable Effects, Health Protection," providing high-quality and accessible treatment options to patients worldwide.

Cision View original content:https://www.prnewswire.co.uk/news-releases/innovative-drug-update--kexing-biopharm-enrolls-first-subject-in-china-based-phase-i-clinical-trial-of-ophthalmic-innovative-drug-gb10-302791530.html

rt.gif?NewsItemId=EN76137&Transmission_Id=202606040709PR_NEWS_EURO_ND__EN76137&DateId=20260604


04.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2339908  04.06.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer